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Abstract
Background: The Oncotype DX® Colon Cancer Assay is a new diagnostic test for determining the likelihood of
recurrence in stage II colon cancer patients after surgical resection using fixed paraffin embedded (FPE) primary
colon tumor tissue. Like the Oncotype DX Breast Cancer Assay, this is a high complexity, multi-analyte, reverse
transcription (RT) polymerase chain reaction (PCR) assay that measures the expression levels of specific cancer-
related genes. By capturing the biology underlying each patient’s tumor, the Oncotype DX Colon Cancer Assay
provides a Recurrence Score (RS) that reflects an individualized risk of disease recurrence. Here we describe its
analytical performance using pre-determined performance criteria, which is a critical component of molecular
diagnostic test validation.
Results: All analytical measurements met pre-specified performance criteria. PCR amplification efficiency for all 12
assays was high, ranging from 96% to 107%, while linearity was demonstrated over an 11 log2 concentration range
for all assays. Based on estimated components of variance for FPE RNA pools, analytical reproducibility and
precision demonstrated low SDs for individual genes (0.16 to 0.32 CTs), gene groups (≤0.05 normalized/aggregate
CTs) and RS (≤1.38 RS units).
Conclusions: Analytical performance characteristics shown here for both individual genes and gene groups in the
Oncotype DX Colon Cancer Assay demonstrate consistent translation of specific biology of individual tumors into
clinically useful diagnostic information. The results of these studies illustrate how the analytical capability of the
Oncotype DX Colon Cancer Assay has enabled clinical validation of a test to determine individualized recurrence
risk after colon cancer surgery.
Background
The emergence of personalized medicine as a central
healthcare theme has led to an explosion of research
dedicated to finding molecular markers for prediction of
disease outcome and treatment benefit. However,
achieving clinical validation for molecular tests has pro-
ven to be challenging given the dual needs for selection
of high quality molecular markers and the provision of
an analytically sound test process for their measure-
ment. Indeed, the clinical utility of molecular
biomarkers may be limited unless they are provided in
the context of a robust, well-characterized diagnostic
test with documented accuracy, precision, and reprodu-
cibility. The Oncotype DX Breast Cancer Assay has met
this standard as an analytically and clinically validated
high complexity, multi-analyte, RT-PCR test to predict
the likelihood of recurrence and response to chemother-
apy in estrogen receptor-positive, node-negative and
node-positive breast cancer patients [1,2]. With over
160,000 tests performed since its launch in 2004, and its
inclusion in the National Comprehensive Cancer Net-
work (NCCN) and American Society Clinical Oncology
(ASCO) clinical practice guidelines, the Oncotype DX
Breast Cancer Assay has become standard of care for
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breast cancer [3-5].
For patients diagnosed with stage II colon cancer, the
decision of whether or not to receive adjuvant che-
motherapy has been a significant challenge, in part due
to limitations in existing methods for assessing recur-
rence risk. Although pathologic T4 stage and mismatch
repair deficiency (MMR-D) can identify patients at sig-
nificantly higher or lower recurrence risk, respectively
[6,7], these two markers account for only 25-30% of
stage II patients. For the majority of stage II colon can-
cer patients, who would be characterized as having stan-
dard risk, there has been a major need for better
prediction of individual recurrence risk [6]. Based on
the results of the clinical validation study of the 12 gene
Oncotype DX Colon Cancer Assay [7], stage II colon
cancer patients (particularly those with T3 disease and
mismatch repair proficient (MMR-P) tumors) are now
empowered to make more informed treatment decisions
with quantitative, individualized recurrence risk infor-
mation based on the molecular profile of their tumor.
The seven cancer-related genes in the Oncotype DX
Colon assay were selected from a panel of 761 genes for
their consistent association with colon cancer recurrence
in 4 large and independent development studies [6].
Three of these genes are associated with activated stroma
(BGN, INHBA and FAP), three represent a cell cycle
pathway (MK167, MYBL2 and MYC) and one can be
characterized as part of an early-response or genotoxic
stress pathway (GADD45B). For each patient, expression
values from the co-expressed stromal genes are aggre-
gated to form a stromal gene score (SGS) and the expres-
sion values of the three cell cycle genes are aggregated to
form a cell cycle gene score (CCGS). The SGS, CCGS
and the expression of GADD45B are combined to gener-
ate the final RS which provides an individualized risk
estimate for colon cancer recurrence (see Figure 1).
The expression levels of these genes may vary both
within and between FPE blocks from the same patient’s
tumor. However, all sources of variability are inherently
incorporated into the clinical validation of the Oncotype
DX Colon Cancer Assay, and therefore embedded within
the estimated risk of disease recurrence obtained for each
RS value. However, one source of variability which can
be controlled in a molecular diagnostic test is that
derived from the assay process (analytical variability). In
fact, it is this source of variability which has to be con-
trolled if a consistent and reliable test result is to be pro-
vided to patients on a daily basis. Prior to performing the
clinical validation study of the 12 gene RS assay we estab-
lished pre-determined assay performance criteria and
performed analytical validation studies, designed to
demonstrate that the process was well-controlled and
capable of reproducibly translating tumor biology into
clinically actionable information. We report here the
design and results of the suite of analytical validation stu-
dies that characterize the performance of the assay.
Methods
Gene selection
The seven cancer-related genes (BGN, MYC, FAP,
GADD45B, INHBA, MK167 and MYBL2)a n df i v er e f e r -
ence normalization genes (ATP5E, GPX1, PGK1,
VDAC2 and UBB) were selected from 761 genes, based
on the results of four development studies which
included over 1800 patients [6].
Tumor blocks and samples
FPE colon cancer blocks (Stage II adenocarcinoma and
mucinous carcinoma) from recent surgeries (within 3-6
months of testing) were obtained under an Institutional
Review Board approved protocol. The selected blocks
were representative of the tumor block type expected to
be received in the clinical reference laboratory (with
respect to tumor type, fixative and age). Samples with
no tumor or very little tumor (< 5% tumor present)
were excluded. In studies where pooled RNA samples
were required, samples were selected to assure accepta-
ble ranges of expression levels for the seven cancer-
related genes.
RNA extraction
RNA extraction was performed using a semi-automated
method, as previously described [8].
Stromal Genes Cell Cycle Genes Individual Reference Genes
BGN MKI67 GADD45B ATP5E
FAP MYC GPX1
INHBA MYBL2 PGK1
VDAC2
UBB
RSu = 0.1263 x Stromal Group Score 
- 0.3158 x Cell Cycle Group Score 
+ 0.3406 x GADD45B 
where:
Stromal Group Score = (BGN + FAP + INHBA)/3
Cell Cycle Group Score = (MYBL2 + Ki-67 + MYC )/3
The RSu (recurrence score unscaled) is then rescaled to be between 0 and 100:
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Figure 1 RS algorithm. Shown are gene names, their associated
gene group and the algorithm for calculation of the Recurrence
Score.
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RNA was quantified using the RiboGreen fluorescence
method (Invitrogen, Carlsbad, CA.), as previously
described [9]. The minimum concentration required for
accurate quantification was 5 ng/μl .A n ys a m p l ew i t h
less than this amount was excluded from the study.
Genomic DNA detection
RNA was tested for residual genomic DNA (gDNA) by
quantitative PCR (qPCR) using an ATCB TaqMan® assay
(see section “TaqMan Primer Probe Design and Gene
Expression Analysis” for details). Six wells containing
2 ng/well RNA were assayed per sample. RNA samples
were failed if more than 2 wells gave a Cycle Threshold
(CT) value of <37. This value represents less than 5 pg
per well (less than 3 copies).
Reverse transcription and qPCR
Reverse transcription was performed as a single, master
reaction using the Omniscript kit (Qiagen, Valencia,
CA) with a gene specific primer (one reverse primer) for
each assay gene. Each primer in the RT reaction was at
a concentration of 50 nmol/L. For the standard assay, a
Tecan workstation was used to dispense RNA at a con-
centration of 2 ng/μl into the RT reaction (2 ng/well
complementary DNA (cDNA) for quantitative PCR
(qPCR)). The dilution series was manually pipetted
using RNA input ranging from 0 to 32 ng/μli nt h eR T
reaction (0 to 32 ng/well of cDNA for quantitative
PCR). RT reactions were performed either in a single
tube (dilution series) or 96-well plate (for standard reac-
tions). The resulting cDNA was distributed to 384-well
plates and PCR forward and reverse primers and Taq-
Man probe were added using a Tecan workstation.
TaqMan® primer probe design and gene expression
analysis
Reference sequences were obtained from NCBI Entrez,
and TaqMan assays designed using a proprietary primer-
design module. Where possible, TaqMan assays were
designed to span introns (ATP5E, BGN, MK167, MYBL2,
PGK1 and VDAC2). Oligonucleotides were purchased
from Integrated DNA Technologies (Coralville, IA). Dual
labeled TaqMan probes have a Fluorescein (6-FAM™)5 ’
reporter and a Black Hole Quencher-2 (BHQ-2®) 3’
quencher. Largest amplicon size was 84 base pairs and
smallest size was 66 base pairs. See Additional file 1
Table S1 for the oligonucleotide sequences and Addi-
tional file 2 Table S2 for amplicon sequences.
TaqMan RT-PCR was performed using Applied Bio-
systems (ABI) Prism 7900HT instruments (7900)
according to manufacturer’s instructions. Reactions were
10 μl volume with cDNA equivalent to 2 ng total RNA
(with the exception of the linearity study, where cDNA
i n p u tr a n g e df r o m2
-10 to 2
5ng/well). Final primer and
probe concentrations were 0.9 μmol/L (primers) and
0.2 μmol/L (probe). PCR cycling conditions were 95°C
for 10 minutes for one cycle, 95°C for 20 seconds, and
60°C for 45 seconds for 40 cycles. Triplicate wells were
run for each assay and each well was classified as “valid”
or “invalid” using pre-defined amplification curve
metrics. The mean CT of the valid wells was used in
subsequent statistical analyses.
Reference gene normalization
Where required, normalization was performed using the
average expression of the five reference genes (ATP5E,
GPX1, PGK1, UBB and VDAC2). These genes were
selected due to low expression variability between
patients in the preliminary clinical development studies
[6] (and data on file, Genomic Health Inc). The mean
(valid) CT for each gene was subtracted from the mean
(valid) CT for the 5 reference genes, then 10 was added
to give a normalized range of expression from 0-15,
where each unit reflects a 2-fold change in expression.
Gene group and Recurrence Score calculation
Genes in the stromal gene group and cell cycle gene
group were selected on the basis of co-expression and
meaningful biological pathway associations, as previously
described [6]. The CCGS was derived from the aggre-
gated, normalized mean CT values for MYC, MKI67 and
MYBL2. The SGS was derived from the aggregated, nor-
malized mean CT values for BGN, FAP and INHBA. The
CCGS, SGS and normalized mean CT for GADD45B are
then entered into an algorithm to generate the RS (see
Figure 1).
Amplification efficiency
Using a pool of FPE RNA samples, two independent
17-point serial dilutions (representing 2
-10 to 2
5ng RNA
equivalent/well) were manually prepared and taken
through RT and then qPCR, with triplicate wells per
gene assay. The mean CT for the two dilution series, at
each RNA input, was averaged to obtain a final non-
normalized CT value. The estimates of amplification effi-
ciencies were calculated for each of the 12 genes using
the formula
Efficiency
slope =−
− 21
1
where slope was estimated from the regression of CT
measurements versus RNA concentration.
Linearity
Using the aggregated, non-normalized CT values from
the 17-point serial dilution, the linearity of CT value as
a function of RNA concentration was evaluated for each
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Krouwer et al., 1993 [10] and recommended by the
National Committee of Clinical Laboratory Standards
(NCCLS) [11], was used to test for linearity over the
range of input RNA concentrations. The polynomial
method evaluates nonlinearity in two parts. The first
part examines whether a second or third order polyno-
mial model fits better than a linear model. If none of
the nonlinear terms in either the second or third order
polynomial models is significant, then linearity is
assumed. If significant nonlinearity is detected, then
comparisons are made between the best-fitting polyno-
mial model and linear polynomial to determine if the
degree of bias is within a predefined allowable limit.
For each gene assay, orthogonal polynomial regression
was used to obtain coefficients and associated tests of
significance for the first (linear), second (quadratic), and
third (cubic) order polynomials. Since precision is
known to vary significantly across different RNA con-
centrations, heteroscedasticity in error variance was
modeled through a log-linear variance model.
The degree of nonlinearity in signal response was
assessed by examining the standard error of the regres-
sion and selecting the higher-order (nonlinear) polyno-
mial model with the best fit. This statistic constituted
t h ea v e r a g ed i f f e r e n c eb e t w e e nt h ed a t aa n dt h em o d e l ,
and so the model with the lowest value provided the
best fit. At each (known) input RNA concentration, the
deviation from linearity (DL) was calculated as follows:
DLi = () −+ () px b b x ii 01
where the values x range from x1...x15,a n dp(xi)w a s
the value of the best-fitting polynomial at point xi. Con-
sequently, DLi i sam e a s u r eo ft h ed i f f e r e n c eb e t w e e n
the nonlinear model and the best-fit straight line at each
of the RNA concentrations.
Analytical sensitivity
The analytical sensitivity of each of the 12 genes was
evaluated separately. Specifically, for each gene assay, a
nonlinear mixed effects model with log-linear variance
function was used to model the heteroscedasticity in
intra-assay response as a function of RNA concentra-
tion. This information was used to estimate the Limit of
Detection (LOD) and Limit of Quantitation (LOQ) of
the assay. For each of the 12 genes, a lower one-sided
95% confidence interval on the CT at zero RNA concen-
tration, ymin, was calculated. The LOD was estimated by
a lower 95% confidence bound on the mean expression
at zero concentration (natural scale). Similarly, the LOQ
was estimated by the inverse prediction of ymin with the
upper one-sided 95% confidence interval of the fitted
calibration model. Analyses were performed using an
iterative estimation scheme involving the PROC MIXED
procedure in SAS version 9.1.
Assay precision and reproducibility
Two FPE RNA pools were created to provide homoge-
neous templates for measuring precision and reproduci-
bility; one pool had a RS in the high recurrence risk
group (RS≥41) and the other had a RS in the low recur-
rence risk group (RS < 30). Using the standard 2 ng/
well RNA equivalent, precision was assessed by estimat-
ing between-day, between-lot, between-7900 instrument
(7900HT Fast Real-Time PCR System, Applied Biosys-
tems), between-plate (within day), and within-plate
variability components and total variability. Reproduci-
bility was assessed by estimating differences in mean
CTs between Tecan workstations used to assemble RT
and qPCR plates. Analyses were performed using the
PROC MIXED procedure in SAS version 9.1.
For assessing precision, a mixed effects analysis of var-
iance (ANOVA) model was used to decompose the total
variability in CT measurements into components of var-
iance due to day, 7900 instrument, oligonucleotide lot
and plate (run) within day, treating Tecan workstations
as a fixed effect. An efficient (algorithmic) experimental
design with G-efficiency > 50% was followed. Two Tecan
workstations were used to assemble the RT and qPCR
plates on five different days, using three different lots of
oligonucleotides and data generated on five different
7900 instruments. For each gene, and each FPE RNA
pool, Restricted Maximum Likelihood (REML) estimates
of the precision of the assay were obtained along with
approximate 95% confidence intervals expressed as rela-
tive standard deviations (RSD) of total variance.
For assessing the reproducibility of the assay, (least
square) mean CT and mean scores between different
combinations of RT and qPCR Tecan workstations were
contrasted.
Assay controls
Prior to clinical validation, a standard RNA template
was run across several 7900 instruments, using various
primer-probe lots to monitor control of the process.
During clinical validation [7], the same RNA was
included on every RT plate at the same concentration as
test samples, and was used as an RT positive control.
Nuclease-free water was used as the RT negative con-
trol. For the quantitative PCR controls, an RNaseP Taq-
Man primer-probe set (Applied Biosystems, Foster City,
CA) was distributed in twelve wells across the 384-well
plate; genomic DNA was added to the qPCR positive
control wells and nuclease-free water to the qPCR nega-
tive control wells.
Clark-Langone et al. BMC Cancer 2010, 10:691
http://www.biomedcentral.com/1471-2407/10/691
Page 4 of 11Results
When an assay result depends on multiple single-value
measurements, it is imperative that the analytical char-
acteristics of each analyte are assessed independently.
Here we describe the analytical performance of the indi-
vidual components of the Oncotype DX Colon Cancer
Assay, which allowed us to confidently proceed to clini-
cal validation.
Amplification efficiency
Amplification efficiencies close to 100% are characteris-
tic of qPCR assays that are robust, reproducible and spe-
cific. The 17-point serial dilution demonstrated that
each gene assay achieved this. Specifically, amplification
efficiencies (summarized in Table 1) were excellent and
ranged from 96% to 107%. Pipette error, the presence of
PCR inhibitors or non-specific amplification (primer-
dimer) may account for efficiencies greater than 100%.
In addition, all genes showed similar efficiencies. This is
an important characteristic of tests which utilize expres-
sion of reference genes to normalize expression of the
test genes [12].
Linearity
The range of expression across patients for each of the
12 genes is large, and therefore it is important to
demonstrate linearity of each gene assay over the poten-
tial range, to ensure accuracy of the result irrespective
of the level of expression. Using the same dataset gener-
ated to assess amplification efficiency, the linearity of
signal response between CT value and RNA concentra-
tion was evaluated for each of the 12 genes. Linear
range estimates and estimated maximal deviation from
linearity at the extremes are provided in Table 2. All
12 genes met the pre-specified acceptance criteria
(a maximum deviation from linearity of 1 CT)o v e ra t
least an 11 log2 concentration range (2
-6 to 2
5)w i t ha
median deviation at the extremes of 0.4 CT.
Analytical sensitivity
Since background noise could impact signal, it is impor-
tant to determine the LOD for each gene. Similarly, it is
important to establish the LOQ for each gene assay to
achieve confidence in the level of expression being
reported. Table 3 summarizes the estimated Limit of
Detection (LOD) and Limit of Quantitation (LOQ) for
each of the 12 genes. The LOD for all 12 genes was
40 CT, thus meeting the pre-specified acceptance criter-
ion of ≥37 CT. The LOQ for all 12 genes was greater
than 36 CT, also meeting the pre-specified acceptance
criterion of ≥35 CT. These values are similar to those
obtained for the 21 genes in the Oncotype DX Breast
Cancer Assay [13].
Analytical precision
Between-7900 instrument, between-primer-probe lot,
and within-PCR plate components of variance
accounted for greater than 80% of total variance in
CT measurements. Between-instrument and between-
primer-probe lot constituted the largest components of
variance. Table 4 lists the estimates of total variance for
non-normalized CT values for each of the two FPE RNA
pools investigated. All genes met the pre-specified
acceptance criterion of 10% on the total % RSD. Total
means and total SD for the SGS, CCGS, GADD45B and
RS are summarized in Table 5. In both the low RS and
high RS FPE RNA pools, the highest SD was 0.04
(normalized/aggregate) CT units for the SGS, 0.05 (nor-
malized/aggregate) CT units for the CCGS, 0.13 (nor-
malized/aggregate) CT units for GADD45B and 1.38 RS
Table 1 Amplification efficiency
Gene Amplification Efficiency (%) Lower 95% Confidence Interval Upper 95% Confidence Interval
ATP5E 96.3 94.4 98.3
BGN 97.7 95.8 99.6
MYC 97.3 95.1 99.6
FAP 103.3 100.0 106.8
GADD45B 106.9 101.7 112.5
GPX1 97.8 95.5 100.2
INHBA 102.9 100.3 105.6
MK167 100.8 97.4 104.5
MYBL2 99.9 97.0 103.0
PGK1 97.0 95.3 98.7
UBB 98.0 95.4 100.6
VDAC2.1 97.1 95.3 98.9
Amplification efficiencies and 95% confidence intervals for the 12 genes. Amplification efficiencies range from 100% ± 7%, and vary due to additive assay error
from the 17-point dilution series, PCR inhibition, or primer-dimer formation which can result in amplification efficiency greater than 100%.
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cal variability would be very unlikely to produce a clini-
cally meaningful change in the risk of recurrence
reported for each patient.
Reproducibility
Table 6 summarizes the largest pair-wise differences in
(least square) mean non-normalized CT between Tecan
workstations by gene for the two FPE RNA pools. Over-
all, the differences in mean CT between Tecan worksta-
tions across all 12 genes and the two FPE RNA pools
were small, all ≤ 0.28 CT. All the genes in the 12-gene
panel met the pre-specified acceptance criteria for
reproducibility.
Assay controls
A control sample was run on twenty-one RT plates
prior to clinical validation of the Oncotype DX Colon
Cancer Assay, and on thirty one RT plates during clini-
cal validation. Figure 2 is a variability chart (Box Plots)
of gene expression for the 12 genes for the RT positive
control run on these fifty two RT plates. It illustrates a
tightly controlled process with standard deviations in
aggregate CT measurements between samples ranging
from 0.19 to 0.33 CT units. Figure 3 provides a histo-
gram of the RNase P (Applied Biosystems. Foster City,
CA) PCR positive controls from all PCR plates gener-
ated prior to and during clinical validation, where a pre-
specified acceptance criterion of 1% coefficient of var-
iance (CV) was applied. During the clinical validation
study, seven PCR plates containing twenty eight samples
(< 2%) failed this 1% CV specification and were there-
fore repeated.
Discussion
A molecular diagnostic test used for treatment planning
in cancer patients must be analytically robust and repro-
ducible so as to enable consistent and accurate transla-
tion of each patient’s tumor biology into clinically
actionable information. The Oncotype DX Colon Cancer
Assay generates a RS for individual patients from the
reference normalized tumor expression level of 7 can-
cer-related genes. These genes were chosen from a
refined list of 48 genes (from an original set of 761 can-
didate genes) which were consistently associated with
colon cancer recurrence in four independent clinical
development studies comprising more than 1800
Table 2 Linear range
Gene Linear Range Quadratic
p-value
Cubic
p-value
Maximum Absolute Deviation from Linearity (CT)
ATP5E 2
-10 to 2
5 ng < 0.01 < 0.01 0.44
BGN 2
-9 to 2
5 ng < 0.01 < 0.01 0.17
MYC 2
-10 to 2
5 ng < 0.01 0.11 0.86
FAP 2
-7 to 2
5 ng < 0.01 < 0.01 0.74
GADD45B 2
-7 to 2
5 ng < 0.01 0.01 0.38
GPX1 2
-10 to 2
5 ng < 0.01 0.04 0.30
INHBA 2
-7 to 2
5 ng < 0.01 < 0.01 0.99
MK167 2
-7 to 2
5 ng < 0.01 < 0.01 0.17
MYBL2 2
-6 to 2
5 ng < 0.01 0.81 0.43
PGK1 2
-8 to 2
5 ng < 0.01 < 0.01 0.56
UBB 2
-10 to 2
5 ng < 0.01 0.08 0.36
VDAC2 2
-10 to 2
5 ng < 0.01 < 0.01 0.23
Using the aggregated, non-normalized CT values from the 17-point serial dilution, the linearity of CT value as a function of RNA concentration was evaluated for
each gene. All genes demonstrated a maximum deviation from linearity less than 1 CT over at least an 11 log2 concentration range (2
-6 to 2
5).
Table 3 Limit of detection (LOD) and limit of quantitation
(LOQ)
Gene LOD (CT) LOQ (CT) Log2 RNA Input (ng) at the LOQ
ATP5E 40.0 36.6 -10
BGN 40.0 36.9 -9
MYC 40.0 39.6 -10
FAP 40.0 38.3 -7
GADD45B 40.0 39.2 -7
GPX1 40.0 37.3 -10
INHBA 40.0 36.5 -7
MK167 40.0 37.1 -7
MYBL2 40.0 37.5 -6
PGK1 40.0 37.4 -8
UBB 40.0 37.6 -10
VDAC2 40.0 39.1 -10
LOD and LOQ were calculated using a nonlinear mixed effects model with
log-linear variance function from the 17-point serial dilution series. LOD for all
12 genes was 40 CT, thus meeting the pre-specified acceptance criterion of
≥37 CT. The LOQ for all 12 genes was greater than 35 CT, also meeting the
pre-specified acceptance criterion of ≥35 CT.
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are represented; cell cycle and stroma-associated. The
heart of the co-expressed stromal gene group is a collec-
tion of extra-cellular matrix (ECM) proteins including
BGN, COL1A1, SPARC and CTHRC1. Cluster analysis
from the development studies show these genes shared
the lowest average distance between clusters (1-Pearson’s
R distance as low as 0.15) [6]. Other subgroups observed
in the stroma-associated gene cluster included the TGFb
signaling pathway (TGFBI, TGFB3, INHBA), early
response genes (EGR1, GADD45B), the WNT pathway
(SFRP2, SFRP4), and invasion related genes (PAI1, OPN,
TIMP2, TIMP3) [6]. Genes within the cell cycle group
included checkpoint control genes and cell cycle regula-
tion genes (such as CDC20, MCM2, MYBL2, CSE1L,
MYC and MK167).
After identifying these biological pathways and genes
as important markers of clinical outcome in stage II
colon cancer, they were used to develop a test to enable
translation of tumor biology into clinically useful infor-
mation. Since biological heterogeneity was inherently
embedded within the clinical validation of the Oncotype
Table 4 Precision for non-normalized CT values
FPE RNA
Pool
Gene Total SD
(CT)
Overall
CT
Total % RSD (95%
CI)
1 ATP5E 0.24 24.86 1
(0.6, 3.3)
1 BGN 0.22 25.89 0.8
(0.5, 1.8)
1 FAP 0.28 29.86 0.9
(0.5, 3.0)
1 GADD45B 0.32 30.81 1.1
(0.6, 3.6)
1 GPX1 0.22 25.7 0.8
(0.5, 2.4)
1 INHBA 0.25 28.52 0.9
(0.5, 2.7)
1 MK167 0.2 28.56 0.7
(0.4, 1.9)
1 MYBL2 0.23 29.27 0.8
(0.5, 1.8)
1 PGK1 0.28 27.61 1
(0.6, 2.3)
1 UBB 0.19 25.68 0.7
(0.5, 1.7)
1 VDAC2 0.25 27.68 0.9
(0.6, 2.1)
1 MYC 0.26 27.62 0.9
(0.6, 2.2)
2 ATP5E 0.23 25.87 0.9
(0.5, 3.7)
2 BGN 0.2 26.66 0.8
(0.5, 1.8)
2 FAP 0.25 30.28 0.8
(0.5, 2.8)
2 GADD45B 0.3 30.6 1
(0.5, 4.5)
2 GPX1 0.19 26.05 0.7
(0.4, 2.8)
2 INHBA 0.23 29 0.8
(0.4, 2.9)
2 MK167 0.19 29.63 0.6
(0.4, 1.6)
2 MYBL2 0.23 30.77 0.8
(0.4, 2.9)
2 PGK1 0.24 28.64 0.8
(0.5, 2.8)
2 UBB 0.16 26.17 0.6
(0.4, 1.6)
2 VDAC2 0.24 28.87 0.8
(0.5, 2.2)
Table 5 Precision for RS and RS components
FPET Pool Score Mean Score Total SD
1 RS 23.6 1.18
2 RS 43.6 1.38
1 SGS 8.2 0.03
2 SGS 8.5 0.04
1 CCGS 7.8 0.04
2 CCGS 6.9 0.05
1 GADD45B 5.5 0.13
2 GADD45B 6.6 0.11
Two FPE RNA pools were created to provide homogeneous templates for
measuring precision. FPE RNA pool 1 represents a sample with a RS in the low
risk group (RS < 30) and FPE RNA pool 2 represents a sample with a RS in the
high risk group (RS≥40). Using the standard 2 ng/well RNA equivalent, precision
was assessed by estimating between-day, between-lot, between-7900
instrument, between-plate (within day), and within-plate variability
components and total variability. Listed are the estimates of total variance for
CCGS (normalized, aggregate CT values), SGS (normalized, aggregate CT values),
GADD45B (normalized, aggregate CT values) and RS for each of the two FPET
pools.
Table 4 Precision for non-normalized CT values
(Continued)
2 MYC 0.24 30.32 0.8
(0.5, 2.5)
Two FPE RNA pools were created to provide homogeneous templates for
measuring precision. FPE RNA pool 1 represents a sample with a RS in the
low risk group (RS < 30) and FPE RNA pool 2 represents a sample with a RS in
the high risk group (RS≥40). Using the standard 2 ng/well RNA equivalent,
precision was assessed by estimating between-day, between-lot, between-
7900 instrument, between-plate (within day), and within-plate variability
components and total variability. Listed are the estimates of total variance for
each gene and each of the two FPET pools using raw CT values. All genes met
the pre-specified acceptance criterion of 10% on the total %RSD.
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Page 7 of 11DX Colon Cancer Assay, any such variability is already
incorporated into the prediction of disease recurrence
provided by each individual patient’sR S .H o w e v e r ,t h e
most important source of variability from the perspec-
tive of daily testing is assay process, or analytical varia-
bility. The 12 RT-qPCR assays and associated processes
were therefore analytically validated using pre-defined
performance criteria prior to clinical validation of the
RS. Analytical validation for the Oncotype DX Colon
Cancer Assay was patterned after the approach used for
the widely accepted Oncotype DX Breast Cancer Assay
[3-5]. At the time the Oncotype DX Breast Cancer
Assay was analytically validated there was no widely
accepted standard for multi-analyte RT-PCR tests.
Therefore, methods commonly used to validate single-
analyte laboratory tests were adapted for the purpose
[13]. Here, all 12 individual genes were shown to be
linear over a 2,000 fold range, and 5 genes (ATP5E,
MYC, GPX1, UBB and VDAC2) were linear over a
32,000 fold range. For all genes, the limit of detection
was at a CT of 40, and the limit of quantitation at a CT
of 36 or greater, providing uniformly high analytical sen-
sitivity for all genes being reported. The sensitivity and
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Figure 2 Variability chart (box-plots) for RT positive controls
run prior to and during clinical validation stratified by gene.A
standard RNA template was run across several 7900 instruments,
using various primer-probe lots prior to and during clinical
validation. The same RNA was included on every RT plate at the
same concentration as test samples, and was used as an RT control.
Nuclease-free water was used as the RT negative control. Standard
deviations in aggregate cycle threshold measurements between
samples ranged from 0.19 to 0.33, showing a highly controlled
process.
Aggregate Cycle Threshold (CT)
Figure 3 Histogram of PCR positive controls (RNaseP) run prior
to and during the clinical validation study. An RNaseP TaqMan
assay, with gDNA as the template, was distributed across twelve
wells of a 384-well qPCR plate and used as the qPCR positive
control. A pre-specified acceptance criterion of 1%CV was applied.
During the clinical validation study, only twenty eight samples (2%)
failed this 1% CV specification, demonstrating a highly controlled
process.
Table 6 Reproducibly
FPET Pool Gene Difference in Mean CT
1 ATP5E 0.17
1 BGN 0.21
1 FAP 0.25
1 GADD45B 0.14
1 GPX1 0.16
1 INHBA 0.18
1 MK167 0.21
1 MYBL2 0.23
1 PGK1 0.28
1 UBB 0.22
1 VDAC2 0.19
1 MYC 0.26
2 ATP5E 0.08
2 BGN 0.08
2 FAP 0.11
2 GADD45B 0.13
2 GPX1 0.09
2 INHBA 0.05
2 MK167 0.1
2 MYBL2 0.15
2 PGK1 0.09
2 UBB 0.11
2 VDAC2 0.11
2 MYC 0.02
FPE RNA pool 1 represents a sample with a RS in the low risk group (RS < 30)
and FPE RNA pool 2 represents a sample with a RS in the high risk group
(RS≥40). To determine reproducibility of the assay, (least square) mean CT and
mean scores between different combinations of RT and qPCR Tecan
workstations were contrasted. Shown is the largest pair-wise differences in
(least square) mean non-normalized CT between Tecan workstations by gene
for the two FPE RNA pools. Overall, the differences in mean CT between Tecan
workstations across all 12 genes and the two FPE RNA pools were small, all
≤0.28 CT.
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ensures robust reporting irrespective of the level of
RNA expression, an attribute which may not be
achieved with DNA microarrays given the lesser
dynamic range of this platform [14,15]. This may in part
account for why assessments and validations of microar-
ray systems have focused on precision or reproducibility,
rather than accuracy [16-20].
The Oncotype DX Colon Cancer Assay is performed
in a high-throughput process using multiple Tecan
robotic workstations. In addition, multiple reagent lots
and 7900 qPCR instruments provide potential sources of
process variability. Therefore, all measureable analytical
sources of variability were assessed to determine total
system variability. Using two FPE RNA pools, an analy-
sis of variance (ANOVA) model was applied to estimate
the total analytical variability in CT measurements for
each separate component of variance. The greatest
source of analytical variability in CT (and therefore gene
scores and RS) came from between-qPCR instruments
and between-primer-probe lot components. However,
even with these components the relative standard devia-
tions (RSD) associated with each gene was still very
small, and well within the pre-defined acceptance criter-
ion of 10%. In fact, the upper bounds of the 95% confi-
dence intervals on the RSD for all the genes in the
12-gene panel were within 10%. The high precision of
the individual genes translates into a similarly high level
of precision for the stromal gene group score (SD≤0.04),
the cell cycle gene group scores (SD≤0.05) and the RS
(SD≤1.38).
Plots from a control sample run prior to and during the
clinical validation study demonstrate consistent stability
for each gene assay. During the clinical validation study,
less than 2% of the qPCR plates had to be repeated
because of failure to meet both qPCR positive and nega-
tive control specifications. Such a well-controlled assay
process is an important element of any prognostic or pre-
dictive molecular test performed in a clinical reference
laboratory used for treatment planning.
The two principal co-expressed gene groups in the
Oncotype DX Colon Cancer Assay have long been
known as important in cancer progression. The expres-
sion levels of an ECM protein (BGN), a fibroblast speci-
f i ci n t e g r a lm e m b r a n es e r i n ep r o t e a s e( FAP), and a
TGFb family member (INHBA) are aggregated in the
colon RS algorithm to form the SGS, where higher
expression is associated with a higher risk of recurrence.
Dvorak first described cancers as wounds that do not
heal [21], and it is now generally accepted that activated
stroma represents a “wound healing response” that can
promote tumor growth, cell migration, invasion and
angiogenesis [22-27]. In the same way that tissue regen-
eration during wound healing involves a complex
relationship between the host and the microenviron-
ment, tumorgenesis is also dependant on extra-cellular
interactions and signals from the stroma. High amounts
of stroma have been associated with poor clinical out-
come in patients with colon cancer [28,29], but as
demonstrated by clinical validation of the Oncotype DX
Colon Cancer Assay, the level of activation and asso-
ciated gene expression within the stroma is strongly
associated with risk of recurrence. GADD45B is entered
into the algorithm as an individual gene, although it
tends to associate with the larger stromal group on clus-
ter analysis [6]. Interestingly, GADD45B is believed to
stimulate BGN expression [30].
The second co-expressed gene group that proved to
be clinically informative as a component of the colon
cancer RS was the cell cycle gene group. In contrast to
the Oncotype DX Breast Cancer Assay, where higher
expression of cell cycle genes (STK15, MYBL2, MK167
and CCNB1) is associated with increased risk of recur-
rence [1,2], higher expression of the colon cell cycle
genes (such as C D C 2 0 ,M C M 2 ,M Y B L 2 ,C S E 1 L ,M Y C
and MK167), was found to correlate with a lower risk of
recurrence [6]. This is consistent with other reported
evidence that cell cycle gene expression correlates with
a good prognosis in colon cancer [31-35]. Garrity et al.
reported only a weak correlation in colon cancer
between MK167 levels and S-phase (the standard mea-
sure of proliferation) [32], indicating that expression of
this gene may not signify rapidly dividing tumors.
Instead, increased expression of these cell cycle check-
point and control genes may represent tightened control
of various stages of the cell cycle in response to DNA
damage or misalignment of chromosomes during mito-
sis. APC is mutated in 80% of sporadic colon carcino-
mas [36] by either allelic loss or mutations in the multi
cluster region (MCR), and there appears to be an inter-
dependence of the two hits [37]. Homozygous deletions
of APC are very rare, and residual APC activity is asso-
ciated with difference biological characteristics depend-
ing on the type of mutation and its associated truncated
protein (N-APC) [38-41]. For example, different APC
mutations have been shown to result in various levels of
b-catenin activation [38,39,42,43] and thus different
growth advantages [40]. APC is also involved in chro-
mosomal segregation, whereby it localizes to the ends of
microtubules within the kinetochore and forms a com-
plex with checkpoint proteins [35,44]. Some N-APC
mutants have been shown to impair spindle checkpoint
and contribute to mis-segregation of chromosomes
[41,45-47]. With tighter cell cycle control and the ability
(albeit a modest one) to undergo apoptosis or mitotic
catastrophe in response to such mitotic errors, a tumor
could reduce its abundance of aneuploidy and chromo-
somal instability (CIN) [48]. Given that CIN is
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Page 9 of 11associated with poor outcome [49-52] it could explain
how high expression of cell cycle and checkpoint genes
(such as CDC20, MCM2, MYBL2, CSE1L, MYC and
MK167) were correlated with a lower risk of recurrence
[6]. Since APC mutations are much rarer in breast can-
cer, it is likely that cell cycle genes (and specifically cell
cycle control genes) do not harbor the same prognostic
information as they do for colon cancer. This possible
connection in colon cancer between different types of
APC mutations, cell cycle control gene expression, CIN
and prognosis warrants further investigation.
Conclusions
In summary, after molecular markers and biological
pathways had been identified in four independent clini-
cal studies, the Oncotype DX Colon Cancer Assay was
developed to translate individual tumor biology into
treatment planning. By requiring the individual compo-
nents of RS to meet stringent analytical performance
criteria, it was possible to clinically validate the Onco-
type DX Colon Cancer Assay and have confidence that
every test performed in the clinical reference laboratory
is done so using a sound and well controlled process.
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and sequence for each gene assay.
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